The study and its comparison
Researchers randomized 191 volunteers with knee osteoarthritis to UC-II, glucosamine plus chondroitin, or placebo. The main outcome was change in total WOMAC score over 180 days. [1]
The 40-milligram daily UC-II regimen improved the overall score compared with both other groups. Selected pain, stiffness and function comparisons also favored it; not every subscale comparison against the active treatment was significant. [1]
What the finding establishes
These are symptom and function outcomes, not proof of regenerated cartilage. InterHealth sponsored the study, two authors were employees and another provided consulting services. The paper described independent study management and statistical analysis. Product identity, duration and sponsorship should accompany the benefit claim. [1]
A hypothetical distinction
Imagine pain improves without an imaging measure of new cartilage. Symptom relief cannot be relabeled structural repair.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study - PMC
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.